Brought to you by 
BMS and SB to co-promote Avandia for Type II diabetes
29 Feb 2000
Executive Summary
Though formal approval is pending, one day after the FDA Endocrinologic and Metabolic Drugs Advisory Committee supported the use of SmithKline Beecham's Avandia for Type II diabetes, SB and Bristol-Myers Squibb agreed to co-promote the product.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS and SB to co-promote Avandia for Type II diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice